Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.
2.

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer.

Chibaudel B, Maindrault-Gœbel F, Bachet JB, Louvet C, Khalil A, Dupuis O, Hammel P, Garcia ML, Bennamoun M, Brusquant D, Tournigand C, André T, Arbaud C, Larsen AK, Wang YW, Yeh CG, Bonnetain F, de Gramont A.

Cancer Med. 2016 Apr;5(4):676-83. doi: 10.1002/cam4.635. Epub 2016 Jan 24.

3.

Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients.

Chang TC, Shiah HS, Yang CH, Yeh KH, Cheng AL, Shen BN, Wang YW, Yeh CG, Chiang NJ, Chang JY, Chen LT.

Cancer Chemother Pharmacol. 2015 Mar;75(3):579-86. doi: 10.1007/s00280-014-2671-x. Epub 2015 Jan 11.

4.

Clinical recovery from surgery correlates with single-cell immune signatures.

Gaudillière B, Fragiadakis GK, Bruggner RV, Nicolau M, Finck R, Tingle M, Silva J, Ganio EA, Yeh CG, Maloney WJ, Huddleston JI, Goodman SB, Davis MM, Bendall SC, Fantl WJ, Angst MS, Nolan GP.

Sci Transl Med. 2014 Sep 24;6(255):255ra131. doi: 10.1126/scitranslmed.3009701.

5.

A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.

Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, Ong A, Wang YW, Yeh CG, Chen LT.

Br J Cancer. 2013 Aug 20;109(4):920-5. doi: 10.1038/bjc.2013.408. Epub 2013 Jul 23.

6.

A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.

Roy AC, Park SR, Cunningham D, Kang YK, Chao Y, Chen LT, Rees C, Lim HY, Tabernero J, Ramos FJ, Kujundzic M, Cardic MB, Yeh CG, de Gramont A.

Ann Oncol. 2013 Jun;24(6):1567-73. doi: 10.1093/annonc/mdt002. Epub 2013 Feb 13.

PMID:
23406728
7.

A soluble chimeric inhibitor of C3 and C5 convertases, complement activation blocker-2, prolongs graft survival in pig-to-rhesus monkey heart transplantation.

Salerno CT, Kulick DM, Yeh CG, Guzman-Paz M, Higgins PJ, Benson BA, Park SJ, Shumway SJ, Bolman RM 3rd, Dalmasso AP.

Xenotransplantation. 2002 Mar;9(2):125-34.

PMID:
11897005
8.

Anti-inflammatory activities of LDP-392, a dual PAF receptor antagonist and 5-lipoxygenase inhibitor.

Qian C, Hwang SB, Libertine-Garahan L, Eckman JB, Cai X, Scannell RT, Yeh CG.

Pharmacol Res. 2001 Sep;44(3):213-20.

PMID:
11529688
9.

A recombinant soluble chimeric complement inhibitor composed of human CD46 and CD55 reduces acute cardiac tissue injury in models of pig-to-human heart transplantation.

Kroshus TJ, Salerno CT, Yeh CG, Higgins PJ, Bolman RM 3rd, Dalmasso AP.

Transplantation. 2000 Jun 15;69(11):2282-9.

PMID:
10868627
10.

Role of C3 cleavage in monocyte activation during extracorporeal circulation.

Rinder CS, Rinder HM, Johnson K, Smith M, Lee DL, Tracey J, Polack G, Higgins P, Yeh CG, Smith BR.

Circulation. 1999 Aug 3;100(5):553-8.

11.

Effects of immune complex formation and complement activation on circulating platelets in the primate.

Birmingham DJ, Hebert LA, Shen XP, Higgins P, Yeh CG, Creasey AA.

Clin Immunol. 1999 Apr;91(1):99-105.

PMID:
10219260
12.

(+/-)-trans-2-[3-methoxy-4-(4-chlorophenylthioethoxy)-5-(N-methyl-N- hydroxyureidyl)methylphenyl]-5-(3,4, 5-trimethoxyphenyl)tetrahydrofuran (CMI-392), a potent dual 5-lipoxygenase inhibitor and platelet-activating factor receptor antagonist.

Cai X, Scannell RT, Yaeger D, Hussoin MS, Killian DB, Qian C, Eckman J, Hwang SB, Libertine-Garahan L, Yeh CG, Ip SH, Shen TY.

J Med Chem. 1998 May 21;41(11):1970-9.

PMID:
9599246
13.

A soluble chimeric complement inhibitory protein that possesses both decay-accelerating and factor I cofactor activities.

Higgins PJ, Ko JL, Lobell R, Sardonini C, Alessi MK, Yeh CG.

J Immunol. 1997 Mar 15;158(6):2872-81.

PMID:
9058824
14.

The effects of soluble recombinant complement receptor 1 on complement-mediated experimental glomerulonephritis.

Couser WG, Johnson RJ, Young BA, Yeh CG, Toth CA, Rudolph AR.

J Am Soc Nephrol. 1995 May;5(11):1888-94.

15.

Complement inhibition with soluble complement receptor type 1 in cardiopulmonary bypass.

Gillinov AM, DeValeria PA, Winkelstein JA, Wilson I, Curtis WE, Shaw D, Yeh CG, Rudolph AR, Baumgartner WA, Herskowitz A, et al.

Ann Thorac Surg. 1993 Mar;55(3):619-24.

PMID:
8383955
16.

Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia-reperfusion in the rat.

Hill J, Lindsay TF, Ortiz F, Yeh CG, Hechtman HB, Moore FD Jr.

J Immunol. 1992 Sep 1;149(5):1723-8.

PMID:
1387151
17.

Role of complement in endotoxin/platelet-activating factor-induced lung injury.

Rabinovici R, Yeh CG, Hillegass LM, Griswold DE, DiMartino MJ, Vernick J, Fong KL, Feuerstein G.

J Immunol. 1992 Sep 1;149(5):1744-50.

PMID:
1324280
18.

Lung injury after deposition of IgA immune complexes. Requirements for CD18 and L-arginine.

Mulligan MS, Warren JS, Smith CW, Anderson DC, Yeh CG, Rudolph AR, Ward PA.

J Immunol. 1992 May 15;148(10):3086-92.

PMID:
1374449
19.

Effect of soluble complement receptor type 1 on natural antibody levels during xenograft rejection.

Pruitt SK, Baldwin WM 3rd, Marsh HC Jr, Lin SS, Yeh CG, Bollinger RR.

Transplant Proc. 1992 Apr;24(2):477-8. No abstract available.

PMID:
1566394
20.

Protective effects of soluble CR1 in complement- and neutrophil-mediated tissue injury.

Mulligan MS, Yeh CG, Rudolph AR, Ward PA.

J Immunol. 1992 Mar 1;148(5):1479-85.

PMID:
1311349
21.

The effect of soluble complement receptor type 1 on hyperacute xenograft rejection.

Pruitt SK, Baldwin WM 3rd, Marsh HC Jr, Lin SS, Yeh CG, Bollinger RR.

Transplantation. 1991 Nov;52(5):868-73.

PMID:
1949173
22.

Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats.

Yeh CG, Marsh HC Jr, Carson GR, Berman L, Concino MF, Scesney SM, Kuestner RE, Skibbens R, Donahue KA, Ip SH.

J Immunol. 1991 Jan 1;146(1):250-6.

PMID:
1824590

Supplemental Content

Support Center